ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

The Cancer Letter’s Paul Goldberg Wins Journalism Award

April 10, 2009

Brain Gliomas Progress When Gene Function Is Lost

April 25, 2003

FDA Approves Inlyta Pill For Renal Cell Carcinoma

January 27, 2012

Ethics Commission To Continue Consideration Of Compensation For Injured Research Subjects

June 20, 1980

In Brief: ONS Forms Six New Special Interest Groups; Four Named To Michigan Breast Cancer Center

April 13, 1990

Upton May Leave NCI Soon, Newell Accepts Post At M.D. Anderson to Head Cancer Prevention

August 17, 1979